Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Greenlee, J. Unger, M. LeBlanc, S. Ramsey, D. Hershman (2016)
Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical TrialsCancer Epidemiology, Biomarkers & Prevention, 26
G. Malietzis, G. Lee, D. Bernardo, Alexandra Blakemore, S. Knight, M. Moorghen, H. Al-Hassi, J. Jenkins (2015)
The prognostic significance and relationship with body composition of CCR7‐positive cells in colorectal cancerJournal of Surgical Oncology, 112
Lisa Martin, Laura Birdsell, N. Macdonald, T. Reiman, M. Clandinin, L. Mccargar, R. Murphy, Sunita Ghosh, M. Sawyer, V. Baracos (2013)
Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 12
S. Shachar, A. Deal, M. Weinberg, K. Nyrop, G. Williams, T. Nishijima, Julia Benbow, H. Muss (2016)
Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based ChemotherapyClinical Cancer Research, 23
T. Iwase, T. Sangai, T. Nagashima, M. Sakakibara, Junta Sakakibara, S. Hayama, Emi Ishigami, Takahito Masuda, M. Miyazaki (2015)
Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patientsCancer Medicine, 5
D. Chan, A. Vieira, D. Aune, D. Aune, E. Bandera, D. Greenwood, A. McTiernan, D. Rosenblatt, I. Thune, I. Thune, R. Vieira, T. Norat (2014)
Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studiesAnnals of Oncology, 25
H. Rier, A. Jager, S. Sleijfer, J. Rosmalen, M. Kock, M. Levin (2017)
Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.Breast, 31
W. Shen, M. Punyanitya, Zimian Wang, D. Gallagher, M. St-Onge, J. Albu, S. Heymsfield, S. Heshka (2004)
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image.Journal of applied physiology, 97 6
B. Williams, J. Mandrekar, S. Mandrekar, S. Cha, A. Furth (2006)
Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes
C. Prado, V. Baracos, L. Mccargar, T. Reiman, M. Mourtzakis, K. Tonkin, J. Mackey, S. Koski, E. Pituskin, M. Sawyer (2009)
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 15
J. Hubbard, H. Cohen, H. Muss (2014)
Incorporating biomarkers into cancer and aging research.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 24
Cécile Contal, J. O'Quigley (1999)
An application of changepoint methods in studying the effect of age on survival in breast cancerComputational Statistics & Data Analysis, 30
K. Starr, C. Pieper, M. Orenduff, S. McDonald, Luisa McClure, Run Zhou, M. Payne, C. Bales (2016)
Improved Function With Enhanced Protein Intake per Meal: A Pilot Study of Weight Reduction in Frail, Obese Older AdultsThe Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 71
M. Kwan, Wendy Chen, Candyce Kroenke, E. Weltzien, J. Beasley, S. Nechuta, E. Poole, Wei Lu, M. Holmes, C. Quesenberry, J. Pierce, X. Shu, B. Caan (2012)
Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling ProjectBreast Cancer Research and Treatment, 132
G. Malietzis, N. Johns, H. Al-Hassi, S. Knight, R. Kennedy, K. Fearon, O. Aziz, J. Jenkins (2016)
Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal CancerAnnals of Surgery, 263
Elizabeth Feliciano, Candyce Kroenke, J. Meyerhardt, C. Prado, P. Bradshaw, M. Kwan, Jingjie Xiao, S. Alexeeff, D. Corley, E. Weltzien, A. Castillo, B. Caan (2017)
Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS StudyJAMA Oncology, 3
A. Villasenor, R. Ballard-Barbash, K. Baumgartner, R. Baumgartner, L. Bernstein, A. McTiernan, M. Neuhouser (2012)
Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL StudyJournal of Cancer Survivorship, 6
C. Prado, J. Lieffers, L. Mccargar, T. Reiman, M. Sawyer, Lisa Martin, V. Baracos (2008)
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.The Lancet. Oncology, 9 7
J. Ligibel, D. Wollins (2016)
American Society of Clinical Oncology Obesity Initiative: Rationale, Progress, and Future Directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 35
E. Fabbro, H. Parsons, C. Warneke, Kalyan Pulivarthi, J. Litton, R. Dev, S. Palla, A. Brewster, E. Bruera (2012)
The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.The oncologist, 17 10
ImportanceSarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown. ObjectiveTo evaluate associations of all 3 body composition measures, derived from clinically acquired CT at diagnosis, with overall mortality in nonmetastatic breast cancer. Design, Setting, and ParticipantsThis observational study included 3241 women from Kaiser Permanente of Northern California and Dana Farber Cancer Institute diagnosed from January 2000 to December 2013 with stages II or III breast cancer. We calculated hazard ratios (HRs) to evaluate the associations of all-cause mortality with sarcopenia, low muscle radiodensity, and total adipose tissue (TAT). Models were adjusted for sociodemographics, tumor characteristics, treatment, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), and other body composition measures. We also evaluated the cross-classification of categories of sarcopenia (yes/no) and tertiles of TAT, with outcomes. Main Outcomes and MeasuresOverall survival time and all-cause mortality. ResultsMedian (range) age of 3241 women included in this study was 54 (18-80) years, and median follow-up was 6.0 years; 1086 patients (34%) presented with sarcopenia, and 1199 patients (37%) had low muscle radiodensity. Among patients with nonmetastatic breast cancer, those with sarcopenia showed higher overall mortality (HR, 1.41; 95% CI, 1.18-1.69) compared with those without sarcopenia. Patients in the highest tertile of TAT also showed higher overall mortality (HR, 1.35; 95% CI, 1.08-1.69) compared with those in the lowest tertile. Low radiodensity was not associated with survival. In analyses of sarcopenia and TAT, highest mortality was seen in patients with sarcopenia and high TAT (HR, 1.89; 95% CI, 1.30-2.73); BMI alone was not significantly related to overall mortality and did not appropriately identify patients at risk of death owing to their body composition. Conclusions and RelevanceSarcopenia is underrecognized in nonmetastatic breast cancer and occurs in over one-third of newly diagnosed patients. Measures of both sarcopenia and adiposity from clinically acquired CT scans in nonmetastatic patients provide significant prognostic information that outperform BMI and will help to guide interventions to optimize survival outcomes.
JAMA Oncology – American Medical Association
Published: Jun 5, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.